Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2016

View Archived Issues

New biomarkers in rheumatoid disease presented at ACR meeting

Arsanis' ASN-100 receives FDA fast track designation

ABC-1183, a novel GSK3/CDK9 inhibitor

EC grants orphan designation to Agilis Biotherapeutics' AGIL-AADC

AmorePacific initiates phase III trial of PAC-14028 in atopic dermatitis

Vertex initiates phase II study of VX-152 combination therapy for cystic fibrosis

A first-in-class small-molecule inhibitor of PD-L1 and TIM-3

Daiichi Sankyo's DS-8201 given FDA fast track designation

First phase Ia/b data for anti-RSPO3 antibody OMP-131R10 in advanced solid tumors

City of Hope and TGen form alliance to advance precision medicine

Axial Biotherapeutics launches with series A financing

Portage Biotech forms new ophthalmic-focused company

Kalyra Pharmaceuticals patents EGFR inhibitors

Wistar Institute discloses EBNA-1 inhibitors

GlaxoSmithKline describes RIP-1 kinase 1 inhibitors

Medshine Discovery develops PDE2A inhibitors and TNF-alpha production inhibitors

Kainos Medicine presents Brd4 inhibitors

Aequus BioPharma synthesizes melanocortin fusion peptide for treating gout

IONIS-ANGPTL3-LRx shows potential to reduce plasma ANGPTL3 and lipids

Ferring Pharmaceuticals and Ache Laboratorios Farmaceuticos form nanotechnology collaboration

Biophytis' Sarconeos safe in SARA-PK clinical study

Aradigm reports topline results from ORBIT-3 and -4 studies of Pulmaquin

Inovio Pharmaceuticals awarded grant for MAb against Zika virus

GALACTIC-HF phase III trial of omecamtiv mecarbil begins

HDAC6 inhibitor ACY-241 given U.S. orphan status for multiple myeloma

Dosing begins in phase I/II study of Agenus' INCAGN-1949

Shire's Cinryze granted U.S. orphan status for acute antibody-mediated renal transplant rejection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...